<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Haas Spears | Activity</title>
	<link>https://www.catswannabecats.com/members/thrilltailor97/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/thrilltailor97/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Haas Spears.</description>
	<lastBuildDate>Wed, 01 Jul 2026 18:37:05 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">b8af857cb67bceec13a819c8baa6e882</guid>
				<title>Haas Spears posted an update: ce daily in the RA programme (0.24 (0.13-0.41)).



 To [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23345/</link>
				<pubDate>Sun, 08 Jun 2025 08:57:47 -0400</pubDate>

									<content:encoded><![CDATA[<p>ce daily in the RA programme (0.24 (0.13-0.41)).</p>
<p> To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).</p>
<p> In the SENSCIS trial, patients with SSc-ILD were randomised to receive nintedanib 150 mg t&hellip;<span class="activity-read-more" id="activity-read-more-23345"><a href="https://www.catswannabecats.com/activity/p/23345/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1534a0140b111d384f6d3535bade4dcf</guid>
				<title>Haas Spears posted an update: TGFβ-SMAD3 signaling is a major driving force for cancer [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/11710/</link>
				<pubDate>Sun, 01 Jun 2025 07:40:51 -0400</pubDate>

									<content:encoded><![CDATA[<p>TGFβ-SMAD3 signaling is a major driving force for cancer metastasis, while BMP-SMAD1/5 signaling can counteract this response. Analysis of gene expression profiles revealed that an increased TGFβ-SMAD3 and a reduced BMP-SMAD1/5 targeted gene expression signature correlated with shortened distant metastasis free survival and overall survival of p&hellip;<span class="activity-read-more" id="activity-read-more-11710"><a href="https://www.catswannabecats.com/activity/p/11710/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f829417879c1332bfdad8cfc7664063a</guid>
				<title>Haas Spears posted an update: Moreover, patients with ECOG 0 treated with IC (TPF or PF) [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/8958/</link>
				<pubDate>Sat, 31 May 2025 21:56:01 -0400</pubDate>

									<content:encoded><![CDATA[<p>Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes.</p>
<p> After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in&hellip;<span class="activity-read-more" id="activity-read-more-8958"><a href="https://www.catswannabecats.com/activity/p/8958/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">fe58e15a50b3b243bf1fa7b671b3cfdf</guid>
				<title>Haas Spears became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/8885/</link>
				<pubDate>Sat, 31 May 2025 21:49:39 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>